Welcome to our dedicated page for CDT Equity SEC filings (Ticker: CDT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The CDT Equity Inc. (NASDAQ: CDT) SEC filings page on Stock Titan provides access to the company’s official disclosures as filed with the U.S. Securities and Exchange Commission. These documents offer detailed information on CDT’s corporate actions, financial reporting, governance decisions, and strategic developments as it operates as a data-driven biopharmaceutical development company.
CDT’s current reports on Form 8-K include items such as the approval and implementation of reverse stock splits, amendments to its certificate of incorporation, and the formal change of its corporate name from Conduit Pharmaceuticals Inc. to CDT Equity Inc. Filings also describe stockholder approvals related to the company’s stock incentive plan, the authorization of additional shares for equity awards, and matters voted on at annual and special meetings.
Other 8-K filings address topics like non-reliance on previously issued interim financial statements and planned restatements. For example, CDT has reported on the reclassification of certain milestone payments to Sarborg Limited from research and development expense to an acquired diagnostic asset, explaining how this affects its condensed consolidated financial statements. These disclosures help readers understand how the company applies accounting standards to its AI and diagnostic-related agreements.
Proxy materials, such as definitive proxy statements on Schedule 14A, provide further insight into CDT’s governance structure, director elections, auditor ratification, and proposals to amend stock plans. They also outline voting requirements, quorum definitions, and procedural details for virtual annual meetings.
On Stock Titan, these filings are complemented by AI-powered summaries that highlight key points from lengthy documents, making it easier to interpret complex sections of 10-Ks, 10-Qs, 8-Ks, and proxy statements. Real-time updates from EDGAR ensure that new CDT filings, including any Form 4 insider transaction reports or future registration statements, are quickly reflected. This allows investors and researchers to review CDT’s regulatory history, corporate actions, and reporting practices in a structured, accessible format.
CDT Equity Inc. entered a Securities Purchase Agreement to acquire approximately 20% of Sarborg Limited in exchange for equity, warrants and future cash. The company will issue 598,006 shares of common stock and pre-funded warrants to purchase up to 109,978,918 additional shares, plus pay Sarborg
CDT Equity Inc. is soliciting stockholder approval at a virtual special meeting on March 17, 2026 to authorize multiple capital and corporate-structure actions. Key items include approval to issue 3,685,815 shares upon exercise of December pre-funded warrants, approval of an equity line permitting up to $25 million or 19.99% (whichever is less) of newly issued shares, and approval to issue up to 109,978,918 shares upon exercise of February pre-funded warrants. The board also seeks authority to effect one or more reverse stock splits at ratios between 1-for-2 and 1-for-100 (aggregate not more than 1-for-250), to increase authorized common shares from 250,000,000 to 500,000,000, and to redomesticate the company to the Cayman Islands. Shares outstanding were 4,420,963 as of the Record Date.
CDT Equity Inc. director Farley Chele Chiavacci reported acquiring new equity-linked interests in connection with a share purchase deal. On February 19, 2026, the director agreed to transfer 18 shares of Sarborg Limited, valued at about
As consideration, the director received 10,553 shares of CDT common stock and pre-funded warrants to purchase up to 1,940,804 CDT common shares at
CDT Equity Inc. Schedule 13G discloses that a group of related reporting persons collectively report 9.9% beneficial ownership of Common Stock as of
The filing shows 255,657 shares as the number with shared voting and dispositive power, Ascent directly holds 204,031 shares, and the ownership percentages are calculated using 2,303,490 shares outstanding and up to 51,626 shares issuable under a Directed Stock Purchase Agreement subject to a 9.99% ownership blocker.
CDT Equity Inc. is registering 22,846,452 shares of common stock for resale by existing holders. The shares relate to stock issued for consulting services, an equity line of credit with Ascent Partners Fund, and a sale-and-purchase agreement with Corvus Capital that includes pre-funded warrants.
This is a resale registration, so CDT will not receive proceeds from investors’ purchases under this prospectus. However, a separate equity line allows CDT, at its option, to sell up to
Corvus, an entity controlled by CDT’s CEO, received CDT shares and 3,685,815 pre-funded warrants as
CDT Equity Inc. is registering 22,846,452 shares of common stock for resale by existing stockholders. The shares come from consulting fees, an equity line of credit with Ascent Partners Fund LLC, and a sale and purchase agreement with Corvus Capital Limited that included pre-funded warrants.
This is a secondary offering, so CDT will not sell any shares or receive proceeds from these resales. The company has also established a $25 million equity line facility with Ascent and sold subsidiary Conduit Pharmaceuticals Limited to Corvus as part of a $7 million settlement paid in stock and pre-funded warrants.
CDT Equity Inc. entered into a directed equity purchase agreement with an institutional investor, creating an equity line of credit facility of up to
The investor is not required to buy shares that would push its beneficial ownership above
CDT Equity Inc. filed its quarterly report for September 30, 2025. The company reported a net loss of
Management disclosed “substantial doubt” about the company’s ability to continue as a going concern. The company plans to seek additional financing and noted its remaining at‑the‑market capacity of approximately
Stockholders’ equity improved to
CDT Equity Inc. approved a 1-for-8 reverse stock split of its common stock, as described in an amendment to its certificate of incorporation filed in Delaware on October 8, 2025. At the effective time on October 10, 2025, every eight issued and outstanding shares of common stock will be combined into one share, while the par value and other terms of the stock remain unchanged.
The common stock is expected to begin trading on a reverse-split-adjusted basis on The Nasdaq Capital Market on October 13, 2025 under the ticker “CDT,” with a new CUSIP number 20678X403. No fractional shares will be issued; instead, stockholders entitled to a fraction will receive cash based on the split-adjusted closing price on October 10, 2025.